Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib vs Prednisone in mCRPC (COMET-1)
NCT01605227Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- Jul 2012
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Exelixis, Inc.. Started Jul 2012; status: completed.
02
Drugs
cabozantinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01605227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605227.